Scale-up and clinical bioavailability assessment of a 45% drug loaded amorphous nanoparticle formulation of a BCS IV compound for oral delivery.

A 45 % drug loaded (DL) amorphous nanoparticle (ANP) formulation for a BCS IV drug demonstrated promising pharmacokinetics in dogs (Purohit, et al., J. Pharm.